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ABSTRACT
Background: Cryptosporidiosis is one of the most important problems among neonatal ruminants. Cryptosporidium parvum 
is the agent causing the disease. Cryptosporidium infection, responsible for diarrhea, dehydration, weight loss and death in 
neonatal ruminants, leads to significant economic losses for producers. In calves naturally or experimentally infected with 
cryptosporidiosis, many agents have been reported to have therapeutic and protective effects. The objective of this study 
was to compare the effectiveness of halofuginone lactate and paromomycin in the treatment of calves naturally infected 
with Cryptosporidium parvum. 
Materials, Methods & Results: Twenty calves between 7 and 20 days of age and naturally infected were included in the 
study. There were two different treatment groups in the study. The first group of calves were administered 100 µg/kg/day 
halofuginone lactate for 7 days and the second group of calves were administered 100 mg/kg/day paromomycin for 7 days. 
In addition, antibiotic and vitamin C were applied to all calves. Jugular venous blood samples were obtained pre-treatment 
and on the 7th day after the treatment. Routine clinical examinations of the calves were performed on days 0, 1, 3, 5 and 7 
and rectal stool samples were collected for the detection of Cryptosporidium oocysts.  Severe diarrhea, dehydration, de-
pression and weight loss were observed in calves in both treatment groups. A significant decrease (P < 0.05) was observed 
for both groups in oocyst count on days 3, 5 and 7 compared to days 0 and 1. Improvements in blood parameters, stool 
characters and clinical scoring of both groups were observed in post-treatment. 
Discussion: Many pharmaceuticals or compounds have been tested for animal with cryptosporidiosis and only very few 
of them have shown a partial protective activity in ruminants when used prophylactically. Halofuginone lactate and paro-
momycin are commonly recommended as both therapeutic and protective agents. However, the effectiveness of the two 
therapeutic agents in natural infections has not been compared and, in the meantime, recommendations for a rational use 
are also not sufficiently documented in calves with cryptosporidiosis. Paromomycin is an aminoglycoside antibiotic used 
to control C. parvum infection in animals. Paromomycin reduces oocyst shedding and the number of days with diarrhea 
in experimentally infected calves when used prophylactically. Halofuginone lactate is a synthetic quinazolinone with 
cryptosporidial activity in the merozoite and sporozoite stages of C. parvum. It is recommended for both therapeutic and 
prophylactic use in cryptosporidiosis. In this study, although paromomycin (100 mg/kg/day for 7 days) and halofuginone 
lactate (100 µg/kg/day for 7 days) led to a decrease in oocyst shedding from day 1, a statistically significant decrease 
(P < 0.05) was observed from day 3. The results of this study show that the decrease in oocyst shedding in both treatment 
groups, improvements in clinical findings and recoveries in hematologic, blood gas and serum biochemistry values are 
similar. Even though these drugs do not eliminate the infection, they decrease both the severity of diarrhea and contribute 
to recovery. In conclusion, the results of this study indicated that halofuginone lactate and paromomycin were effective 
in the treatment of calves naturally infected with cryptosporidiosis. Therefore, we recommend that both drugs should be 
used in the treatment of calves naturally infected with Cryptosporidium parvum.  
Keywords: cryptosporidiosis, calves, paromomycin, halofuginone lactate.
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INTRODUCTION
Cryptosporidiosis, which causes neonatal di-
arrhea, has a high prevalence disease throughout the 
world [4,7,25]. Clinical cryptosporidiosis is observed 
in calves of 7-30 days old and continues for 4-17 days. 
The calves with diarrhea are usually lethargic, anorexic 
and dehydrated. High fever and straining may also be 
observed. While variable morbidity is reported, the 
mortality rate is low. The severity of the disease may 
vary depending on other pathogens and co-infections. 
In severe cases, death may be seen due to dehydration 
and cardiovascular collapse [6,9,25].
In calves naturally or experimentally infected 
with Cryptosporidium parvum, many agents have been 
reported to have therapeutic and protective effects. 
However, only two of these agents, halofuginone lac-
tate and paromomycin, have been licensed for calves 
in some countries. Halofuginone is a plant alcaloid 
isolated from Dichroa febrifuga and synthetically pro-
duced [23]. It has been reported that it is effective on 
cryptosporidiosis. It shows this effect on the merozoite 
and sporozoite stages of C. parvum [10,14]. Halofugi-
none lactate reduces the severity of cryptosporidiosis, 
delays the start of infection and reduces oocyst shed-
ding, and is recommended for calves as a therapeutic 
and protective agent [3,10,11,13,14]. Paromomycin, 
another effective drug, is a large-spectrum antibiotic in 
the aminoglycosides group produced by Streptomyces 
rimosus var. paromomycinus. Unlike other amino-
glycosides, it has gram-positive and gram-negative 
activity. Paromomycin has a weak absorption from 
the gastrointestinal region. This provides an advantage 
when used for the treatment of certain bacterial and 
protozoan infections of the gastrointestinal system [8]. 
Studies have shown that paromomycin is highly effec-
tive in prophylaxis and causes no toxicity in calves, 
lambs and goats naturally and experimentally infected 
with C. parvum [5,15,28]. 
Halofuginone lactate and paromomycin are 
commonly recommended as both therapeutic and 
protective agents. The effectiveness of these two drugs 
on natural infections has not been compared and the 
information on their rational use is not sufficient. The 
aim of this study is to compare the effectiveness of 
halofuginone lactate and paromomycin in the treatment 
of calves naturally infected with cryptosporidiosis and 
to demonstrate the clinical recovery status during the 
treatment process.
MATERIALS AND METHODS
Animals and experimental procedure
This study was conducted with 20 calves 
aged 7-20 days with diarrhea, diagnosed as having 
C. parvum. It was carried out in the Farm Animal 
Clinic of the Faculty of Veterinary Medicine of Sel-
cuk University. The calves were divided randomly 
into two groups according to the drug administered. 
The first group of calves (n = 10) were administered 
100 µg/kg/day halofuginone lactate (Halocur®)1 for 
7 days and the second group of calves (n = 10) were 
administered 100 mg/kg/day paromomycin (Gabbro-
col®)2 for 7 days. All calves included in the study were 
administered fluid therapy depending on dehydration 
degree and base deficit level, 16 mg kg-1 intramuscular 
sulfadoxine+trimethoprim (Animar®)2 injection once a 
day for 7 days and 1000 mg vitamin C (Injacom C®)2 
injection once a day for 7 days. Eight of the calves in 
the first group were Holstein, 1 was Simmental and 1 
was Norwegian Red, whereas all calves in the second 
group were Holstein.
Blood sampling
Blood samples for blood gas, hematological 
and biochemical analyses were taken from jugular 
vein pre-treatment (day 0) and on 7th day after the 
treatment. Blood gas and hematological samples were 
analyzed within 15 min after the blood collection. 
Tubes without anticoagulants were left for coagula-
tion at room temperature for 30 min and centrifuged 
at 2500 g for 10 min and serums were removed and 
kept at -20°C until the analysis.
Hematological, biochemical and blood gas analyses
Blood white blood cell (WBC), red blood 
cell (RBC), hematocrit (Hct), hemoglobin (Hg) and 
platelet (PLT) levels of calves were determined us-
ing hematological analyzer (MS4VET)3. Blood pH, 
pO2, pCO2, glucose, sodium (Na+), potassium (K+), 
lactate, base excess (BE), bicarbonate (HCO3-) and 
oxygen saturation (O2 SAT) levels were determined 
using a blood gas analyzer (GEM Premier Plus)4. 
Serum blood urea nitrogen (BUN), creatinine, as-
partate aminotransferase (AST), gamma glutamyl 
transferase (GGT), alkaline phosphatase (ALP), 
total protein and albumin concentrations of calves 
were determined using commercial kits and an auto-
analyzer (BS-200)5.
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Clinical examination and stool sampling
Routine clinical examinations of calves were 
performed on days 0, 1, 3, 5 and 7 and rectal stool 
samples were collected using plastic stool containers 
for the detection of Cryptosporidium oocysts.
Determination of Cyptosporidium parvum oocysts
Stool samples were spread onto plates contain-
ing isotonic NaCl solution and dried at room tempera-
ture. Dried preparations were fixed in methyl alcohol 
for 1 min and stained with basic fuchsin solution (4 
g basic fuchsin, 20 mL 95% ethanol, 8 mL melted 
crystal phenol and 100 mL distilled water) for 4 min. 
Preparations were rinsed in 50% ethyl alcohol and 
washed in tap water for 3-5 s. They were decolorized 
with 1% sulphuric acid for 2 min and washed in tap 
water. After staining with methylene blue for 1 min, 
they were washed in tap water once more and dried. 
Evaluation of preparations
Immersion oil was used to examine the stained 
preparations under microscope with a magnification of 
100×. The number of oocysts in 20 different randomly 
selected microscope fields were taken into account for 
each preparation. Oocyst count (scoring) was assessed 
as follows: no oocysts: negative (-); a single oocyst 
in a few fields: rare (+); 1-5 oocysts: low (++); 6-10 
oocysts: moderate (+++); >10 oocysts: high (++++). 
Statistical analysis
The data were expressed as mean and stan-
dard error of the mean (Mean ± SEM). The ANOVA 
multiple range test was used to determine the dif-
ference within groups during the treatment process. 
The Paired-samples t test was used to determine the 
differences between pre-treatment and post-treatment 
hematological, blood gas and biochemical parameters. 
The difference between the two groups was determined 
using the independent t test. The statistical significance 
level was accepted to be P < 0.05. 
RESULTS
Clinical findings
The scoring was performed according to the cri-
teria for clinical examination findings (body temperature, 
respiratory rate, pulse, capillary refill time, dehydration 
degree, conjunctiva status, appetite, mental status, posture 
and stool property) given in Table 1 and changes in clinical 
scoring throughout the treatment are given in Figure 1.
Figure 1. Changes in clinical scoring of calves with cryptosporidiosis before and during the treatment.
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Table 1. Clinical scoring table for calves with cryptosporidiosis.
Clinical Score T (oC) DD (%)
CRT 
(sec) Mucosa Suckle reflex Mental Status
Fecal 
character
0 38-39.5 No 1-2 Normal Normal Normal Normal
1 39.6-40 4-6 3-4 Hyperemic Reluctant Slightly Depressive Mild Water
2 40.1-41 8-10 5-6 Pale Poor Depressive Watery
3 <38 or >41 > 10 ≥ 7 Cyanosis Absent Unconsciousness Very watery
T: temperature; DD: The degree of dehydration; CRT: Capillary refill time.
Oocyst shedding
Changes in oocyst shedding of calves in the 
study on day 0, and days 1, 3, 5 and 7 after the treatment 
are given in Figure 2. There was a significant decrease 
(P < 0.05) in both groups in oocyst shedding on days 
3, 5 and 7, compared to days 0 and 1.
Hematological analysis
Changes in the hematological parameters of 
calves before (day 0) and after the treatment (day 7) 
are given in Table 2.  Although certain changes in pa-
rameters were observed in both groups between day 0 
and day 7, there was no statistically significant change 
(P < 0.05). In terms of differences within the groups, a 
significant decrease (P < 0.05) in the WBC, RBC, Hb 
and Hct values of the first group was observed on day 
7, compared to day 0. However, there was a significant 
increase (P < 0.05) in the PLT level of the second group 
on day 7, compared to day 0.
Blood gas analysis
Changes in the hematological parameters 
of calves on day 0 and day 7 are given in Table 3. 
A significant difference (P < 0.05) was determined 
between the groups in the K+ level only.  In terms 
of differences within groups, a significant increase 
(P < 0.05) was found in pH, pCO2, Na+, HCO3- and 
BE levels and a significant decrease (P < 0.05) 
was found in pO2, K+ and lactate levels for the first 
group on day 7 compared to day 0. A significant 
increase (P < 0.05) was found in the Na+ level and 
a significant decrease (P < 0.05) was found in the 
glucose level for the second group on day 7 com-
pared to day 0.
Figure 2. Changes in oocyst shedding of calves with cryptosporidiosis before and during the treatment. a,b,cWithin 
groups statistical significant.
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Table 2. Changes in hematological parameters of calves with cryptosporidiosis before and during the treatment.
Parameter
Day 0 
Mean ± SEM
Day 7 
Mean ± SEM P
1 P2
WBC (103/µL)
Group 1 (n = 10) 12.22 ± 0.98 9.39 ± 0.54 < 0.05
> 0.05
Group 2 (n = 10) 9.97 ± 1.74 11.02 ± 2.09 > 0.05
RBC (106/µL)
Group 1 (n = 10) 8.38 ± 0.51 7.24 ± 0.65 < 0.05
> 0.05
Group 2 (n = 10) 7.38 ± 0.38 6.93 ± 0.44 > 0.05
HB (g/dL)
Group 1 (n = 10) 10.30 ± 0.69 8.73 ± 0.72 < 0.05
> 0.05
Group 2 (n = 10) 9.04 ± 0.59 8.53 ± 1.06 > 0.05
HT (%)
Group 1 (n = 10) 29.59 ± 1.71 24.51 ± 2.36 < 0.05
> 0.05
Group 2 (n = 10) 26.43 ± 2.10 25.44 ± 2.76 > 0.05
PLT (103/µL)
Group 1 (n = 10) 467.44 ± 55.85 696.67 ± 254.16 > 0,05
> 0,05
Group 2 (n = 10) 429.50 ± 50.48 599.80 ± 93.70 < 0,05
WBC: white blood cell; RBC: red blood cell; Hb: hemoglobin; Hct: hematocrit; PLT platelet. P1=Statistically significant 
P value within groups; P2=Statistically significant P value between groups.
Table 3. Changes in blood gas parameters of calves with cryptosporidiosis before and during the treatment.
Parameter
Day 0
Mean ± SEM
Day 7
Mean ± SEM P
1 P2
pH
Group 1 (n = 10) 7.33 ± 0.03 7.42 ± 0.01 < 0.05
> 0.05Group 2 (n = 10) 7.34 ± 0.04 7.40 ± 0.02 > 0.05
pCO2 (mm Hg)
Group 1 (n = 10) 37.89 ± 1.72 47.11 ± 2.11 < 0.05
> 0.05Group 2 (n = 10) 41.67 ± 2.41 43.71 ± 3.46 > 0.05
pO2 (mm Hg)
Group 1 (n = 10) 27.67 ± 2.08 24.11 ± 2.06 < 0.05
> 0.05Group 2 (n = 10) 24.44 ± 2.90 25.29 ± 2.00 > 0.05
Na+ (mmol/L)
Group 1 (n = 10) 125.22 ± 2.46 139.00 ± 1.36 < 0.05
> 0.05Group 2 (n = 10) 131.78 ± 2.20 138.71 ± 1.38 < 0.05
K+ (mmol/L)
Group 1 (n = 10) 5.20 ± 0.36 4.08 ± 0.10 < 0.05
< 0.05Group 2 (n = 10) 4.23 ± 0.15 4.03 ± 0.20 > 0.05
Glucose (mg/dL)
Group 1 (n = 10) 84.89 ± 6.24 82.89 ± 6.69 > 0.05
> 0.05Group 2 (n = 10) 86.56 ± 5.88 67.29 ± 11.03 < 0.05
Lactate (mmol/L)
Group 1 (n = 10) 1.47 ± 0.22 0.76 ± 0.13 < 0.05
> 0.05Group 2 (n = 10) 1.11 ± 0.15 0.84 ± 0.27 > 0.05
HCO3- (mmol/L)
Group 1 (n = 10) 20.6 ± 2.05 30.57 ± 1.70 < 0.05
> 0.05Group 2 (n = 10) 24.69 ± 3.11 27.46 ± 2.70 > 0.05
BE (mmol/L)
Group 1 (n = 10) -4.89 ± 2.21 5.38 ± 1.66 < 0.05
> 0.05Group 2 (n = 10) -2.23 ± 3.24 2.59 ± 2.96 > 0.05
O2 SAT (%)
Group 1 (n = 10) 46.11 ± 5.43 43.56 ± 4.96 > 0.05
> 0.05Group 2 (n = 10) 37.78 ± 5.60 45.14 ± 4.49 > 0.05
pH: concentration of hydrogen ions; pCO
2
: partial pressure of carbon dioxide; pO2: partial pressure of oxygen; 
Na+: sodium; K+: potassium; HCO3-: bicarbonate;  BE: base excess; O2 SAT. %: oxygen saturation. P1=Statistically 
significant P value within groups; P2 = Statistically significant P value between groups.
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Table 4. Changes in biochemical parameters of calves with cryptosporidiosis before and during the treatment.
Parameter Day 0Mean ± SEM
Day 7
Mean ± SEM P
1 P2
BUN (mg/dL)
Group 1 (n = 10) 35.89 ± 8.27 15.89 ± 1.50 < 0.05
> 0.05
Group 2 (n = 10) 28.57 ± 7.42 19.29 ± 3.02 > 0.05
Creatinine (mg/dL)
Group 1 (n = 10) 1.44 ± 0.13 1.11 ± 0.05 < 0.05
> 0.05
Group 2 (n = 10) 1.40 ± 0.14 1.34 ± 0.16 > 0.05
AST (U/L)
Group 1 (n = 10) 57.11 ± 17.88 32.89 ± 2.06 > 0.05
< 0.05
Group 2 (n = 10) 44.71 ± 6.24 48.71 ± 4.23 > 0.05
GGT (U/L)
Group 1 (n = 10) 101.22 ± 24.72 42.11 ± 8.06 < 0.05
> 0.05
Group 2 (n = 10) 119.43 ± 34.44 68.71 ± 16.62 > 0.05
ALP (U/L)
Group 1 (n = 10) 159.56 ± 17.04 101.56 ± 9.71 < 0.05
< 0.05
Group 2 (n = 10) 96.43 ± 10.73 89.14 ± 5.94 > 0.05
Total Protein (g/dL)
Group 1 (n = 10) 5.78 ± 0.42 4.78 ± 0.22 < 0.05
> 0.05
Group 2 (n = 10) 5.19 ± 0.34 4.96 ± 0.24 > 0.05
Albumin (g/dL)
Group 1 (n = 10) 3.55 ± 0.14 3.24 ± 0.12 > 0.05
> 0.05
Group 2 (n = 10) 3.34 ± 0.15 3.33 ± 0.06 > 0.05
BUN: blood urea nitrogen; AST: aspartate aminotransferase; GGT: gamma glutamyl transferase; ALP: alkaline 
phosphatase. P1=Statistically significant P value within groups; P2 = Statistically significant P value between groups.
Serum biochemical analysis
Changes in serum BUN, creatinine, AST, GGT, 
ALP, total protein and albumin concentrations of calves 
before (day 0) and after the treatment (day 7) are given 
in Table 4. While no statistically significant difference 
was observed between the groups on day 0 and day 
7 in serum BUN, creatinine, GGT, total protein and 
albumin concentrations, a significant difference (P < 
0.05) was found between day 0 ALP levels and day 
7 AST levels.  In terms of differences within groups, 
a significant decrease (P < 0.05) was found in BUN, 
creatinine, GGT, ALP and total protein levels for the 
first group on day 7 compared to day 0. Although 
decreases and increases were present for the second 
group as well, no statistically significant difference 
was observed.  
DISCUSSION
Cryptosporidiosis is one of the most important 
problems among neonatal ruminants. C. parvum, the 
agent causing disease, has been reported to be one of 
the significant etiological agents of neonatal diarrhea 
seen in the first week of calves’ life [2,24]. Crypto-
sporidium parvum infection, responsible for diarrhea, 
dehydration, weight loss and death (up to 50%) in neo-
natal ruminants, leads to significant economic losses 
for producers [2]. Insufficient immunoglobulin intake 
in infected calves, prevalence of the disease, severity 
of diarrhea and involvement of other etiological agents 
are among the important reasons behind the increase 
in mortality [24]. Infected calves may exhibit clinical 
symptoms ranging from asymptomatic clinical find-
ings to diarrhea and dehydration [26]. In this study, 
severe diarrhea, dehydration, depression and weight 
loss were observed in calves in both treatment groups 
(Figure 1). Diarrhea in calves leads to financial loss, 
and lost energy and time due to care, treatment (oral/
intravenous fluid therapy and drug administration) and 
hygienic measures [2,19,26]. Also, it has been reported 
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that mortality increases due to other enteric pathogen 
(E. coli and rotavirus) infections seen simultaneously 
with C. parvum [24,25]. The most important problem 
related to cryptosporidiosis is the lack of an effective 
drug to prevent and treat the disease. In severe cryp-
tosporidiosis outbreaks, it is absolutely essential to 
use anti-cryptosporidial drugs to control the disease. 
Many pharmaceuticals or compounds have 
been tested for animal cryptosporidiosis and only very 
few of them have shown a partial protective activity in 
ruminants when used prophylactically. These can be 
listed as halofuginone lactate, paromomycin, cyclo-
dextrins, azithromycin [18], nitazoxanide, activated 
charcoal and wood vinegar liquid [20,26,27,29]. 
Halofuginone lactate and paromomycin are 
commonly recommended as both therapeutic and pro-
tective agents. However, the effectiveness of the two 
therapeutic agents in natural infections has not been 
compared and, in the meantime, recommendations for 
a rational use are also not sufficiently documented in 
calves with cryptosporidiosis.
Paromomycin is an aminoglycoside antibi-
otic used to control C. parvum infection in animals 
[12,16,28]. Paromomycin reduces oocyst shedding and 
the number of days with diarrhea in experimentally 
infected calves when used prophylactically [5]. In this 
study, it was observed that the severity of diarrhea started 
to decrease from the second day of paromomycin use, 
clinical findings related to cryptosporidiosis improved 
and post-treatment hematological, serum biochemical 
and blood gas findings returned to normal values (Figure 
1, Tables 2-4). It has been reported that paromomycin 
administration (at 100 mg kg-1) for 11 consecutive days 
beginning 1 day before oral inoculation stops oocyst 
shedding and reduces severity of diarrhea, whereas oo-
cyst shedding begins at or near the end of paromomycin 
administration at a dose of 25 mg kg-1 or 50 mg kg-1 
[5]. It has been stated that daily oral administration of 
paromomycin at 100 mg kg-1 for 21 days from birth has 
a prophylactic value for goats in a natural cryptosporidi-
osis outbreak [12]. The same dose of paromomycin has 
been found to be effective in both experimentally [28] 
and naturally [1] infected goats. Paromomycin has been 
found to reduce both oocyst output and severity of clini-
cal symptoms in lambs when administered at 100 mg kg-1 
per day for three consecutive days and at 200 mg kg-1 
per day for two days [28]. In this study, on the other 
hand, although paromomycin administration at 100 mg/
kg/day led to a decrease in oocyst shedding from day 1 
(Figure 2), a statistically significant decrease (P < 0.05) 
was observed from day 3 (Figure 2).
Halofuginone lactate is a synthetic quinazo-
linone with cryptosporidial activity in the merozoite 
and sporozoite stages of C. parvum [10]. It is recom-
mended for both therapeutic and prophylactic use in 
cryptosporidiosis. It has been reported that halofugi-
none lactate use reduces the severity and mortality of 
cryptosporidiosis in calves [11]. In this study, clinical 
(Figure 1), hematological (Table 2), blood gas (Table 
3) and biochemical (Table 4) findings in calves with 
cryptosporidiosis improved during the period following 
halofuginone lactate use. Clinical studies have shown 
that halofuginone has a cryptosporidial activity in the 
merozoite and sporozoite stages of C. parvum [10]. It 
has been reported that halofuginone lactate is an effec-
tive drug against cryptosporidiosis in calves [13,21], 
goats [22] and lambs [17]. Petermann et al. [22] have 
reported that halofuginone lactate administered at 100 
µg kg-1 for 10 days reduces oocyst shedding, diarrhea 
and mortality in goats experimentally infected with 
cryptosporidiosis. Halofuginone lactate administra-
tion (60 and 120 µg kg-1) considerably reduces oocyst 
shedding during the clinical phase of the disease in 
calves experimentally infected with cryptosporidi-
osis [21]. In this study, although halofuginone lactate 
administration at 100 µg/kg/day led to a decrease in 
oocyst shedding from day 1 (Figure 2), a statistically 
significant decrease (P < 0.05) was observed from day 3 
(Figure 2), but severity of clinical findings significantly 
decreased (P < 0.05) from day 2. 
The results of this study show that the decrease 
in oocyst shedding in both treatment groups, improve-
ments in clinical findings and recoveries in hemato-
logic, blood gas and serum biochemistry values are 
similar. Even though these drugs do not eliminate the 
infection, they decrease both the severity of diarrhea 
and contribute to recovery.
CONCLUSIONS
In conclusion, the results of this study indicated 
that halofuginone lactate (100 µg/kg/day for 7 days) 
and paromomycin (100 mg/kg/day for 7 days) were 
effective in the treatment of calves with cryptosporidi-
osis. Therefore, we recommend that both drugs should 
be used in the treatment of calves naturally infected 
with Cyptosporidium parvum.
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